Calquence plus chemoimmunotherapy approved in the US for …
Jan 17, 2025 · AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously …
Fixed-duration Calquence plus venetoclax, - AstraZeneca
Jul 29, 2024 · Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s Calquence (acalabrutinib) in combination with …
Calquence combination regimen demonstrated statistically …
May 2, 2024 · As part of an extensive clinical development programme, AstraZeneca is currently evaluating Calquence alone and in combination for the treatment of multiple B-cell blood …
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, …
Jul 29, 2024 · CALQUENCE is a Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior …
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy …
Jan 17, 2025 · AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously …
CALQUENCE combination regimen demonstrated ... - AstraZeneca US
May 2, 2024 · As part of an extensive clinical development program, AstraZeneca is currently evaluating CALQUENCE alone and in combination for the treatment of multiple B-cell blood …
CALQUENCE® (acalabrutinib) capsules - AstraZeneca US
Start CALQUENCE at Cycle 1 (each cycle is 28 days). Start obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescribing information for recommended dosing. …
FDA approves acalabrutinib with bendamustine and rituximab
On January 16, 2025, the FDA granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell …
Calquence: Uses, Dosage, Side Effects, Warnings - Drugs.com
Oct 15, 2024 · Calquence (acalabrutinib) is a targeted cancer treatment for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) in …
Calquence tablet formulation approved in the EU for ... - AstraZeneca
Feb 22, 2023 · AstraZeneca’s tablet formulation of Calquence (acalabrutinib) has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic …